24 Apr , 2025 By : Debdeep Gupta
Shares of Thyrocare Technologies jumped 20 percent to Rs 921 per share on April 24 after the company reported strong financial performance for the January to March quarter (Q4FY25).
So far this year, the stock of this diagnostics company has declined by 4.5 percent, underperforming the benchmark Nifty 50, which has risen by 2 percent during the same period.
For the quarter ended March 2025, the company reported a 21.9 percent year-on-year increase in net profit, which stood at Rs 21.7 crore, compared to Rs 17.8 crore in the same quarter last year. The profit growth was driven by improved operating performance and a steady rise in the number of diagnostic tests conducted.
Revenue for the quarter rose by 21.3 percent to Rs 187.2 crore, up from Rs 154.3 crore in Q4FY24. The company’s earnings before interest, taxes, depreciation, and amortisation (EBITDA) recorded a sharper growth, rising 70.5 percent to Rs 57.8 crore.
As a result, the EBITDA margin improved to 30.9 percent, compared to 22 percent in the same quarter a year ago. This indicates better cost management and improved operational efficiency.
The company’s Board has recommended a final dividend of Rs 21 per equity share for FY25, which will be subject to approval from shareholders.
Currently, about two brokerages cover Thyrocare Technologies, and both have issued a strong “buy” rating on the stock.
Thyrocare, based in Navi Mumbai, runs a large network of diagnostic and preventive healthcare laboratories across India. In recent quarters, the company has focused on expanding its test offerings and strengthening its digital presence, which has supported revenue growth driven by higher testing volumes.
0 Comment